<DOC>
	<DOCNO>NCT01543594</DOCNO>
	<brief_summary>The biologic drug target TNFa , IL-6 , IL-1 , T cell , B cell represent fundamental discovery treat rheumatic patient whose disease appear refractory conventional therapy . These biologic drug register human therapy year , thereby investigator miss long-term data safety efficacy . Aim study register clinical data patient rheumatoid arthritis spondyloarthritis begin treatment biologic drug order ass long-term safety efficacy real life .</brief_summary>
	<brief_title>Italian Registry Arthritis Biologic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Clinical diagnosis Rheumatoid arthritis , Ankylosing spondylitis , Psoriatic arthritis Patients active disease refractory traditional disease modify drug ( methotrexate , leflunomide , sulphasalazine , cyclosporine , hydrossiclorochine ) Patients eligible begin conventional biologic therapy Any criterion exclude treatment biologic drug accord international guideline</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Seronegative polyarthritis</keyword>
	<keyword>Biologic drug</keyword>
	<keyword>Safety efficacy biologics polyarthritis</keyword>
</DOC>